Evidence map›Paper›PMID 29212276›Full record

ArticleOncotarget2017

Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk.

Jialin Xiao, Lauren Howard, Junxiang Wan, Emily Wiggins, Adriana Vidal, Pinchas Cohen, Stephen J Freedland

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Mitochondria-derived peptides in aging and healthspan.The Journal of clinical investigation · 2022
    Review
  13. Extending human healthspan and longevity: a symposium report.Annals of the New York Academy of Sciences · 2022
    Article
  14. Expression Profile of MouseJournal of lifestyle medicine · 2021
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Mitonuclear genomics and aging.Human genetics · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jialin XiaoLeonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
Lauren HowardDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.
Junxiang WanLeonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
Emily WigginsDivision of Urology, Veterans Affairs Medical Center, Durham, North Carolina, USA.
Adriana VidalDepartment of Surgery, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Pinchas CohenLeonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
Stephen J FreedlandDivision of Urology, Veterans Affairs Medical Center, Durham, North Carolina, USA.
University of Southern California · USCedars-Sinai Medical Center · USDuke University · US

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
The Role of the Glucose-regulated Protein GRP78/BiP in Stress Resistance and AginP01AG034906 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MITCHELL, JAMES R. · 2011 to 2016
$9.3M
A family of novel mitochondrially-encoded peptides and their role in agingR01AG034430 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COHEN, PINCHAS · 2009 to 2012
$1.2M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS P50 CA092131NIA NIH HHS P01 AG034906NIA NIH HHS R01 AG034430
6 · The paper itself

Abstract

contextMitochondrial DNA mutations and dysfunction are associated with prostate cancer (PCa). Small humanin-like peptide-2 (SHLP2) is a novel mitochondrial-encoded peptide and an important mitochondrial retrograde signaling molecule.

objectiveTo determine whether serum SHLP2 concentration is associated with PCa risk and whether associations are race-specific.Design, Setting and Participants: Patients undergoing prostate biopsy were recruited from the Durham Veterans Affairs hospital. Serum was collected prior to biopsy and SHLP2 measured by ELISA. We selected 200 men for analysis (100 negative biopsies and 100 PCa cases; 100 black and 100 white).

resultsMean SHLP2 levels were significantly higher in white controls versus black controls and SHLP2 was significantly higher in white controls versus white PCa cases. In contrast, there was no significant difference in SHLP2 levels between black controls and black cases. SHLP2 levels > 350-pg/ml ruled out PCa with ≥ 95% accuracy in both races.

conclusionsLower SHLP2 was linked with increased PCa risk in white men, but no significant association was observed in black men. While SHLP2 > 350-pg/ml ruled out PCa in both races with high accuracy, SHLP2 was unrelated to PCa grade. These data suggest the circulating mitochondrial-derived peptide hormone, SHLP2 plays a key role in the development and racial disparity of prostate cancer.

Indexed as

aginghealth disparityhumanin-like-peptidemitochondriaretrograde signaling

Identifiers

PMID29212276
PMCPMC5706922
OpenAlexW2744056450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.